Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at [email protected]
The associate professor of neurology at Columbia University gave clinical insight on what neurologists and other neuromuscular specialists can expect from the ALS/frontotemporal dementia track at this year’s MDA Clinical & Scientific Conference. [WATCH TIME: 3 minutes]
After 90 days of treatment, investigators observed positive findings on microdystrophin expression, as well as reductions in markers of muscle injury and stress, and muscle breakdown and dystrophic regeneration.
Matthew B. Harms, MD, an associate professor of neurology at Columbia University Irving Medical Center, an MDA Care Center, gave clinical insights on the advances in ALS genetic research and what clinicians can expect from the ALS/FTD track at the 2025 MDA Clinical & Scientific Conference.
Jonathon Parker, MD, PhD, an assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona, provided commentary on the promise and roadblocks behind stem cell approaches in epilepsy.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on chronic demyelinating inflammatory polyneuropathy (CIDP).
Also known as SNK01, the novel NK cell manufacturing technology enables large-scale ex vivo production and expansion of NK cells.
Andrei Alexandrov, MD, chair of the department of neurology at the University of Arizona College of Medicine, covered the latest advancements in stroke care from ISC 2025, from expanding thrombectomy indications to evolving imaging techniques.
The pharmacokinetic exposure for both sumatriptan and zavegepant was comparable when coadministered, with all ratios remaining within the bioequivalence range of 80%-125%.
Amlenetug, a human monoclonal antibody that recognizes and binds to all major forms of extracellular α-synuclein, is currently being assessed in a large-scale phase 3 trial to determine its therapeutic potential as a treatment for MSA.
Stroke neurologists Lauren Sansing, MD, MS, FAHA, FANA, and Bijoy Menon, MD, MSc, FRCPC, provided a post-conference perspective on the emerging data and research presented at the 2025 International Stroke Conference.
Expected to conclude in late 2026, the trial will feature 30 patients with Jordan’s syndrome, aged 9-45 years, who will be tested for a 24-week treatment period.
This new option, along with updated prescribing information, is expected to allow for easier administration and storage, enhancing the overall treatment experience.
A minor difference in relapse rates at month 8 between rituximab and placebo narrowed by month 12, indicating no long-term treatment advantage.
The John David Eaton Chair in Multiple Sclerosis at the University of Toronto gave an overview for the upcoming ACTRIMS Forum, highlighting key sessions, themes, and advances in the multiple sclerosis field.
Troriluzole, a new chemical entity and third-generation novel prodrug that modulates glutamate, would become the first approved agent for SCA, pending the FDA’s clearance.
A significant number of pregnancies in NMOSD patients experienced relapses postpartum, with 50% of pregnancies showing complications for both mother and fetus.
Monthly cycles of low-dose IL-2, or COYA 301, resulted in statistically significant decreases in proinflammatory biomarkers and increases in anti-inflammatory cytokine IL-4 vs placebo.
Phase 1/2 long-term data showed tividenofusp alfa significantly reduced central and peripheral biomarkers to near-normal levels while improving liver volume, hearing thresholds, adaptive behavior, and cognition in most participants.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the International Stroke Conference (ISC).
The 32-week study will enroll 15–20 adults aged 18–80 with Parkinson's-related hyposmia, featuring a 24-week treatment period of twice-daily CYR-064 nasal sprays.
In addition to failing to separate itself on the primary end point, EVT + best medical care was associated with higher rates of serious adverse events (33.9% vs 25.7%) and mortality (13.3% vs 8.4%) compared to best medical care alone.
The group of women neurologists provided commentary on the critical areas of women-focused research in neurology, from clinical trial participation to addressing workforce challenges.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Véronique Miron, PhD. [LISTEN TIME: 17 minutes]
Panelists explore the challenges and opportunities for women in neurology, offering practical advice for young professionals navigating the field.
The trial evaluates safety, remyelination, and functional outcomes, including changes in low contrast letter acuity, MRI myelination measures, and MS disease activity.
Compared with Alzheimer disease, those with behavioral variant FTD demonstrated increased light sleep (N1%) and reduced deep sleep (N3%), alongside altered sleep dynamics, such as higher transitions between N1 sleep and wake states.
Over a 52-week treatment period, patients who continued on bexicaserin and those who switched from placebo demonstrated notable decreases in motor seizures, further supporting the agent’s development.
In this episode, women neurologists share their personal experiences navigating challenges in neurology, offering insights into mentorship, work-life balance, and career advancement.
SPN-830 is a wearable subcutaneous infusion device designed to deliver continuous treatment throughout the waking day, ensuring more consistent control of OFF time.
A group of empowering women leaders in neurology explore the transformative impact of women neurologists on the medical workforce and the strides toward a more inclusive neurology field.
